Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.

Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP).

Cancer. 2018 Nov 13. doi: 10.1002/cncr.31835. [Epub ahead of print]

PMID:
30423211
2.

MBD4: guardian of the epigenetic galaxy.

Busque L, Godley LA.

Blood. 2018 Oct 4;132(14):1468-1469. doi: 10.1182/blood-2018-08-867044. No abstract available.

PMID:
30287469
3.

Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil.

Busque L, Buscarlet M, Mollica L, Levine RL.

Stem Cells. 2018 Sep;36(9):1287-1294. doi: 10.1002/stem.2845. Epub 2018 Jun 8. Review.

PMID:
29883022
4.

Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host.

Meisel M, Hinterleitner R, Pacis A, Chen L, Earley ZM, Mayassi T, Pierre JF, Ernest JD, Galipeau HJ, Thuille N, Bouziat R, Buscarlet M, Ringus DL, Wang Y, Li Y, Dinh V, Kim SM, McDonald BD, Zurenski MA, Musch MW, Furtado GC, Lira SA, Baier G, Chang EB, Eren AM, Weber CR, Busque L, Godley LA, Verdú EF, Barreiro LB, Jabri B.

Nature. 2018 May;557(7706):580-584. doi: 10.1038/s41586-018-0125-z. Epub 2018 May 16.

5.

Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A.

Buscarlet M, Provost S, Zada YF, Bourgoin V, Mollica L, Dubé MP, Busque L.

Blood. 2018 Jul 19;132(3):277-280. doi: 10.1182/blood-2018-01-829937. Epub 2018 May 15.

PMID:
29764839
6.

Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study.

Perreault S, Shahabi P, Côté R, Dumas S, Rouleau-Mailloux É, Feroz Zada Y, Provost S, Mongrain I, Dorais M, Huynh T, Kouz S, Diaz A, Blostein M, de Denus S, Turgeon J, Ginsberg J, Lelorier J, Lalonde L, Busque L, Kassis J, Talajic M, Tardif JC, Dubé MP.

Clin Cardiol. 2018 May;41(5):576-585. doi: 10.1002/clc.22948. Epub 2018 May 15.

7.

Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.

Bowman RL, Busque L, Levine RL.

Cell Stem Cell. 2018 Feb 1;22(2):157-170. doi: 10.1016/j.stem.2018.01.011. Review.

PMID:
29395053
8.

Identification of the genetic determinants responsible for retinal degeneration in families of Mexican descent.

Villanueva A, Biswas P, Kishaba K, Suk J, Tadimeti K, Raghavendra PB, Nadeau K, Lamontagne B, Busque L, Geoffroy S, Mongrain I, Asselin G, Provost S, Dubé MP, Nudleman E, Ayyagari R.

Ophthalmic Genet. 2018 Jan-Feb;39(1):73-79. doi: 10.1080/13816810.2017.1373830. Epub 2017 Sep 25.

9.

Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.

Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Quebec CML Group.

Am J Hematol. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29. No abstract available.

10.

DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions.

Buscarlet M, Provost S, Zada YF, Barhdadi A, Bourgoin V, Lépine G, Mollica L, Szuber N, Dubé MP, Busque L.

Blood. 2017 Aug 10;130(6):753-762. doi: 10.1182/blood-2017-04-777029. Epub 2017 Jun 27.

11.

Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.

Thiant S, Moutuou MM, Laflamme P, Sidi Boumedine R, Leboeuf DM, Busque L, Roy J, Guimond M.

Blood Cancer J. 2017 Apr 7;7(4):e551. doi: 10.1038/bcj.2017.29.

12.

HSPCs are marathon and not sprint relay athletes.

Busque L.

Blood. 2017 Mar 16;129(11):1406-1407. doi: 10.1182/blood-2017-02-763516. No abstract available.

13.

Clinical-Scale Rapid Autologous BK Virus-Specific T Cell Line Generation From Kidney Transplant Recipients With Active Viremia for Adoptive Immunotherapy.

Lamarche C, Orio J, Georges-Tobar V, Pincez T, Goupil M, Dahmani A, Carli C, Brasey A, Busque L, Delisle JS.

Transplantation. 2017 Nov;101(11):2713-2721. doi: 10.1097/TP.0000000000001698.

PMID:
28230645
14.

Psychological Profiles in the Prediction of Leukocyte Telomere Length in Healthy Individuals.

Starnino L, Busque L, Tardif JC, D'Antono B.

PLoS One. 2016 Oct 27;11(10):e0165482. doi: 10.1371/journal.pone.0165482. eCollection 2016.

15.

Human blood cell levels of 5-hydroxymethylcytosine (5hmC) decline with age, partly related to acquired mutations in TET2.

Buscarlet M, Tessier A, Provost S, Mollica L, Busque L.

Exp Hematol. 2016 Nov;44(11):1072-1084. doi: 10.1016/j.exphem.2016.07.009. Epub 2016 Jul 27.

PMID:
27475703
16.

Laboratory Investigation of Myeloproliferative Neoplasms (MPNs):  Recommendations of the Canadian Mpn Group.

Busque L, Porwit A, Day R, Olney HJ, Leber B, Éthier V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V.

Am J Clin Pathol. 2016 Oct;146(4):408-22. doi: 10.1093/ajcp/aqw131. Review.

PMID:
27686169
17.

Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms.

Szuber N, Lamontagne B, Busque L.

J Clin Pathol. 2016 Jul 27. pii: jclinpath-2016-203940. doi: 10.1136/jclinpath-2016-203940. [Epub ahead of print]

PMID:
27466382
18.

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.

Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Keir C, Warsi G, Lin FP, Mauro MJ.

Clin Lymphoma Myeloma Leuk. 2016 May;16(5):286-96. doi: 10.1016/j.clml.2016.02.002. Epub 2016 Feb 16.

19.

Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.

Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G, Roy DC, Busque L, Delisle JS, Bambace N, Bernard L, Sabry W, Roy J.

Bone Marrow Transplant. 2016 Apr;51(4):529-35. doi: 10.1038/bmt.2015.319. Epub 2015 Dec 21.

PMID:
26691426
20.

Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.

Sirhan S, Busque L, Foltz L, Grewal K, Hamm C, Laferriere N, Laneuville P, Leber B, Liew E, Olney HJ, Prchal J, Porwit A, Gupta V.

Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):715-27. doi: 10.1016/j.clml.2015.07.650. Epub 2015 Aug 7.

PMID:
26433906

Supplemental Content

Loading ...
Support Center